Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Blood cancer patients with COVID-19 fare better with convalescent plasma
(Washington University in St. Louis) A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma -- the pale yellow liquid in blood that is rich in antibodies -- from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Zanubrutinib Better Than Ibrutinib in CLL/SLL? Zanubrutinib Better Than Ibrutinib in CLL/SLL?
An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Combination of two oral drugs boosted survival rates for leukemia patients from 83% to 96%
Two leukemia drugs work okay on their own - but work much better together - a new study shows. Patients had a 96 percent survival rate and a 75 percent remission rate thanks to the drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2021 Category: Consumer Health News Source Type: news

1980 to 2017 Saw Improved Survival for Acute Myeloid Leukemia
THURSDAY, June 10, 2021 -- From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged≥70 years, according to a study published in the June 15 issue of Cancer. Koji Sasaki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

Combination targeted therapy provides durable remission for patients with CLL
(University of Texas M. D. Anderson Cancer Center) A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 8, 2021 Category: Pharmaceuticals Authors: Sonia Waraich Source Type: news

Venetoclax Shows Activity Against T-ALL in Children Venetoclax Shows Activity Against T-ALL in Children
Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia in children and young adults.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors, follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. Today’s BTD marks the 11th received by Janssen’s ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ibrutinib for chronic lymphocytic leukaemia in Italy: high discontinuation rates for costly therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
(Impact Journals LLC) Chronic lymphocytic leukemia (CLL) is characterized by gradual accumulation of neoplastic B cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Study identifies risk for some childhood cancer patients developing secondary leukaemia
(Wellcome Trust Sanger Institute) New study used whole genome sequencing to gain further understanding of why some children develop secondary leukaemia after neuroblastoma treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 28, 2021 Category: Biology Source Type: news

New drug combo found effective against high-risk leukaemia
(Children's Cancer Institute Australia) Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news

When cancer cells " put all their eggs in one basket "
(Cold Spring Harbor Laboratory) Normal cells usually have multiple solutions for fixing problems that may arise. But cancer cells may " put all their eggs in one basket, " getting rid of all backup plans and depending on just one solution. CSHL Professor Christopher Vakoc's lab discovered that a particular type of blood cancer, acute myeloid leukemia, came to depend on a single DNA repair method. They developed a drug that shut down the remaining pathway in lab-grown cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 25, 2021 Category: Drugs & Pharmacology Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommend...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen ’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
We reported initial findings for teclistamab at ASCO 2020, and study updates have observed a deepening of responses that have shown to be durable in a significant percentage of patients with relapsed or refractory multiple myeloma,” said Amrita Y. Krishnan, M.D., Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and Chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, and study investigator. “Teclistamab exposure was sustained across the dosing interval and exceeded target levels, and consistent T-cell activation was ob...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dental school researcher gets approval to begin clinical trials for cancer therapy
(Rutgers University) A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received US Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany's discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

New insight into when CAR T is effective against childhood leukaemia
(University College London) Scientists and clinicians at UCL and Great Ormond Street Hospital (GOSH) studying the effectiveness of CAR T-cell therapies in children with leukaemia, have discovered a small sub-set of T-cells that are likely to play a key role in whether the treatment is successful. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

From mice to men: Study reveals potential new target for treating acute myeloid leukemia
(AlphaMed Press) A study released in STEM CELLS indicates that blocking transforming growth factor beta 1 (TGFβ1) could improve hematopoiesis in patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

Researchers develop first-in-class inhibitors against key leukemia protein
(Michigan Medicine - University of Michigan) Researchers have develop first-in-class inhibitors against ASH1L, a key protein in the development and progression of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2021 Category: Cancer & Oncology Source Type: news

UAMS Researcher Gets $1.27M for Cancer Study
A researcher with the Winthrop P. Rockefeller Cancer Institute gets a five-year, $1.27 million grant to work toward developing two treatment options for acute myeloid leukemia patients. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 11, 2021 Category: American Health Source Type: news

Gene therapy offers potential cure to children born without an immune system
An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.Severe combined immunodeficiency due to adenosine deaminase deficiency, or ADA-SCID, is caused by mutations in theADA gene that creates the enzyme adenosine deaminase, which is essential to a functioning immune system.For children with the condition, even day-to-day activities like going to school or playing with friends can lead to dangerous, life-threatening infections...
Source: UCLA Newsroom: Health Sciences - May 11, 2021 Category: Universities & Medical Training Source Type: news

Efficacy of BNT162b2 mRNA COVID-19 Vaccine Lower in Patients With CLL
THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody responses (NAbs) in elderly patients with multiple myeloma (MM) versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news

Philip Schofield hails 'big step forward' cancer treatment that's saving lives
A GAME-CHANGING treatment for acute lymphoblastic leukaemia - a rare cancer of the blood cells - has been discovered. Philip Schofield remarked on the findings on ITV's This Morning on Monday. (Source: Daily Express - Health)
Source: Daily Express - Health - May 4, 2021 Category: Consumer Health News Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
(University of Copenhagen - The Faculty of Health and Medical Sciences) T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this. Now, researchers from the University of Copenhagen have found a combination treatment that could benefit these patients and increase the survival rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Study finds potential therapeutic target for pediatric acute myeloid leukemia
(Nemours) Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Researchers identify potential combination therapy for aggressive lung cancer
(University of California - Los Angeles Health Sciences) The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 4, 2021 Category: International Medicine & Public Health Source Type: news

Atrium Health Levine Children ’s begins FDA-approved CAR T-cell therapy treatment
Juan Bravo, 10, was diagnosed with leukemia in 2019 and relapsed in May 2020. With the support of his pediatric care team at Atrium Health Levine Children ’s, family and community, Juan had undergone several treatments. In March 2021, he became eligible to receive a new treatment: CAR T-cell therapy. Juan became the first patient at Levine Children’s Hospital – and in the Charlotte region – to begin the process to fight his relapsed leukemia. Learn more about cancer care at Levine Children’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 1, 2021 Category: Biotechnology Authors: Atrium Health Source Type: news

Atrium Health Levine Children ’s begins FDA-approved CAR T-cell therapy treatment
Juan Bravo, 10, was diagnosed with leukemia in 2019 and relapsed in May 2020. With the support of his pediatric care team at Atrium Health Levine Children ’s, family and community, Juan had undergone several treatments. In March 2021, he became eligible to receive a new treatment: CAR T-cell therapy. Juan became the first patient at Levine Children’s Hospital – and in the Charlotte region – to begin the process to fight his relapsed leukemia. Learn more about cancer care at Levine Children’s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 1, 2021 Category: Health Management Authors: Atrium Health Source Type: news

Healthcare use and costs for childhood acute lymphoblastic leukaemia differ by treatment protocol in Ontario, Canada
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
(University of Texas M. D. Anderson Cancer Center) A Phase II trial at MD Anderson tound that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

New genetic target for blood cancer treatment
(Wellcome Trust Sanger Institute) Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these poor-prognosis cancers (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Avocado discovery may point to leukemia treatment
(University of Guelph) A compound in avocados may ultimately offer a route to better leukemia treatment, says a new University of Guelph study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2021 Category: Cancer & Oncology Source Type: news